Why This Biotech Owns The Aging Population Trade

Walking through the oncology ward at Cedars-Sinai last week, I noticed something interesting. The pharmacy techs were wheeling around more Amgen (AMGN) products than I’d seen in months.

Repatha for cholesterol management, EVENITY for osteoporosis, and their expanding biosimilars portfolio. It got me thinking about why Wall Street keeps sleeping on this biotech behemoth.

It’s easy to ignore Amgen, especially with the world obsessed over the sexy new weight-loss drugs from Novo Nordisk (NVO) and Eli Lilly (LLY). Unknown to many, though, this company quietly built the most diversified biologics empire in the industry.

I’ve watched pharma companies rise and fall for two decades, and the survivors always have one thing in common: they don’t bet everything on a single therapeutic area.

Amgen spreads its risk across oncology, rare diseases, inflammation, and general medicine. Smart money recognizes defensive positioning when it sees it.

The recent Q2 numbers tell a story that goes beyond the headline 9% revenue growth to $9.2 billion. Volume jumped 13% year-over-year, which signals something crucial that most investors overlook.

In healthcare, volume growth means doctors are actually prescribing more of your drugs, not just charging higher prices. That’s organic demand, and it’s the holy grail of pharmaceutical investing.

When I see 15 products delivering double-digit sales growth simultaneously, that’s not luck. That’s systematic execution across multiple therapeutic areas.

Let’s break down what’s really happening with their key franchises.

Repatha sales surged 31% because cardiologists finally understand what some of us have known for years: this isn’t just another cholesterol drug. It’s becoming the standard of care for high-risk cardiovascular patients.

With an estimated 100 million patients needing LDL cholesterol-lowering therapies globally, we’re talking about a market that’s barely scratched.

Most portfolio managers focus on the current $1.1 billion in annual Repatha sales, but they’re missing the bigger picture. This drug has blockbuster potential that’s still unfolding.

Evenity represents an even more compelling opportunity that most people don’t grasp. The osteoporosis market is about to explode, and it has nothing to do with new drug discoveries. It’s pure demographics.

Every healthcare investor should have this number memorized: by 2030, one in five Americans will be 65 or older.

Osteoporosis isn’t a disease that responds to lifestyle changes or preventive care. It requires pharmaceutical intervention, period. Amgen has treated 250,000 patients with Evenity so far, but management estimates 90% of the 2 million high-risk patients remain untreated.

The U.S. osteoporosis treatment market is projected to hit $6.1 billion by 2034. Do the math.

The biosimilars business deserves special attention because it demonstrates strategic thinking that separates great biotech companies from mediocre ones.

While branded drug sales face inevitable patent cliffs, Amgen positioned itself to profit from both sides of the equation. Their biosimilars revenue jumped 40% to $661 million, and they’re targeting upcoming patent expirations on Keytruda and Opdivo.

This isn’t just opportunistic. It’s a brilliant portfolio construction that provides revenue stability while their innovative pipeline matures.

Speaking of pipelines, here’s something a lot of people consistently get wrong about biotech investing. They focus on individual drug candidates instead of platform capabilities.

Amgen’s bispecific T-cell engager platform generated 14% growth in its oncology portfolio, reaching $2.2 billion in revenue. This isn’t about one successful drug. It’s about a technological approach that can generate multiple products across different cancer types.

That’s the difference between buying a lottery ticket and investing in a sustainable competitive advantage.

The financial metrics reveal a company that’s mastering the biotech profit equation. A 45% GAAP operating margin isn’t just impressive; it’s evidence of operational excellence in an industry where most companies burn cash for years.

The 19% net income margin ranks among the sector leaders, while a 99% return on equity reflects aggressive capital allocation through share repurchases. These are more than simple vanity metrics. They demonstrate management’s ability to convert scientific innovation into shareholder returns.

Current valuation makes this particularly interesting for income-focused investors. The 3.4% dividend yield comes with a sustainable 42% payout ratio and 13 consecutive years of growth.

But here’s the kicker: the forward P/E of 13.1 sits well below the historical average of 14.7. For a company posting 21% adjusted EPS growth with multiple growth catalysts ahead, that’s compelling value territory.

The regulatory environment presents both challenges and opportunities that require an insider perspective to evaluate properly.

Medicare drug price negotiations create headline risk, but Amgen’s diversified portfolio and international exposure provide insulation that smaller biotechs lack. The potential ban on direct-to-consumer TV advertising might actually benefit established players like Amgen by reducing marketing noise from competitors with inferior products.

At its current price, Amgen offers something rare in today’s biotech landscape: a combination of defensive characteristics, multiple growth drivers, and reasonable valuation.

The company isn’t betting everything on unproven science or single-indication drugs. Instead, it’s systematically building market-leading positions across therapeutic areas with confirmed demand and demographic tailwinds.

For those willing to look beyond the latest biotech fad, this represents a genuine buy-the-dip opportunity in a name that should anchor any serious healthcare portfolio.